The oncology biotechnology sector comprises numerous prominent enterprises dedicated to developing breakthrough cancer treatments, targeted therapies, and immunotherapies. Notable examples include Seagen (acquired by Pfizer), Blueprint Medicines, Kura Oncology, Coherus BioSciences, BeOne Medicines, and Mirati Therapeutics (acquired by Bristol Myers Squibb). These companies harness advanced molecular biology, precision medicine, and clinical trial pipelines to discover novel mechanisms that combat various forms of cancer globally.